#United States #Menlo Park #Lung Cancer #Maverix Medical #Carla Jung

Carla Jung Takes the Helm as CEO of Maverix Medical

Maverix Medical, a pioneering company centered on transforming the diagnosis and treatment of lung cancer, has exciting news! The firm has just appointed Carla Jung as its new Chief Executive Officer. This strategic move aims to bolster the company’s growth while refining its product offerings and market strategies.

Jung, with an impressive 29 years of experience in the medical technology sector, previously served as the Chief Commercial Officer at Maverix, where she played a key role in driving substantial revenue growth—over 30% year-on-year—since joining the company. Under her guidance, Maverix has significantly expanded its customer base and commercial footprint, particularly after acquiring Thoracent in early 2025. This acquisition was pivotal in establishing Maverix as a formidable player in the lung cancer market, building a specialized platform that promises to enhance clinical outcomes for patients and healthcare professionals alike.

In a statement regarding Jung’s leadership, Duke Rohlen, Founder and CEO of Ajax Health, praised her ability to motivate and inspire her team. "Carla is a seasoned professional who delivers results by seeking to bring out the best in everyone around her," he noted, underscoring her commitment to empowering physicians with advanced solutions for their patients.

Alongside Jung's appointment, the company announces a leadership transition whereby David Beylik, formerly the Chief Operating Officer, is elevated to Executive Chair. This move ensures that Maverix will benefit from Beylik’s extensive knowledge and insight as the company embarks on this new chapter. Additionally, Brian Lynch, who has been instrumental in building the sales organization at Thoracent, will now take on the roles of Chief Revenue Officer and President of the Medical Device Division.

Carla Jung’s credentials reflect her capability to lead Maverix during this crucial period. Before joining Maverix, she was the Vice President of Coronary and Renal Denervation at Medtronic, where she successfully launched more than ten cardiovascular products over 13 years. Furthermore, her diverse background includes eleven years at Boston Scientific and a foundation in women's health with Eli Lilly. Jung holds an MBA from Columbia University and a BA from Villanova University, adding to her robust profile in the medtech landscape.

Expressing enthusiasm about her new role, Jung stated, "I’m honored to lead this team. In lung cancer, earlier diagnosis is one of the most powerful ways to improve outcomes. Our ambition is to make an impact across the entire continuum of care, from detection through treatment, with the goal of helping more patients survive this disease."

With its commitment to innovation and caregiver support, Maverix Medical is set for a future marked by growth and enhanced patient outcomes. The company's mission is clear: to revolutionize lung cancer diagnosis and treatment, bringing cutting-edge technologies to improve and save lives. As Carla Jung leads this mission, stakeholders in the medical community and beyond will be keenly watching to see how Maverix Medical transforms its vision into reality.

In summary, Jung’s ascent to the CEO role at Maverix Medical is not just a leadership change; it represents a forward-thinking strategy aimed at making significant strides in lung cancer care, ultimately impacting countless lives positively. The coming years will be crucial for Maverix, as it seeks to fulfill its promise of innovation and excellence in an ever-evolving healthcare environment.